APG Asset Management N.V. Boosts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

APG Asset Management N.V. boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1,704.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 368,390 shares of the medical research company's stock after acquiring an additional 347,975 shares during the period. APG Asset Management N.V. owned 0.10% of Thermo Fisher Scientific worth $185,077,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Norges Bank purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth $3,149,754,000. Proficio Capital Partners LLC increased its holdings in Thermo Fisher Scientific by 68,617.0% in the 4th quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock worth $396,810,000 after acquiring an additional 761,649 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at about $377,901,000. Grantham Mayo Van Otterloo & Co. LLC boosted its position in Thermo Fisher Scientific by 140.7% during the fourth quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,093,866 shares of the medical research company's stock worth $569,062,000 after purchasing an additional 639,467 shares during the period. Finally, Lindsell Train Ltd purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $211,858,000. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at $59,506,950.58. This trade represents a 7.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by company insiders.

Remove Ads

Thermo Fisher Scientific Price Performance

TMO traded up $10.47 during midday trading on Friday, hitting $437.91. The stock had a trading volume of 2,656,544 shares, compared to its average volume of 1,696,843. The company has a market cap of $165.21 billion, a P/E ratio of 26.49, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a 1 year low of $409.85 and a 1 year high of $627.88. The business has a fifty day moving average of $510.56 and a 200 day moving average of $539.34. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a $0.43 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.39%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.41%.

Wall Street Analyst Weigh In

TMO has been the topic of several recent research reports. Raymond James restated an "outperform" rating and set a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price for the company in a research note on Friday, January 10th. Royal Bank of Canada set a $693.00 price target on Thermo Fisher Scientific in a research report on Friday, January 31st. UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Finally, Scotiabank increased their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average price target of $647.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.